Ipamorelin
Ipamorelin is a selective growth hormone secretagogue investigated in preclinical studies for its ability to stimulate growth hormone release and support musculoskeletal recovery. It remains a research chemical without FDA approval for human use and is utilized solely within laboratory settings.
What is Ipamorelin?
Ipamorelin is a synthetic peptide classified as a selective growth hormone secretagogue. It was developed to mimic the natural stimulatory effects on growth hormone release without significant activation of other hormonal axes. Structurally, it is a pentapeptide with a molecular formula of C38H49N9O5 and has been extensively characterized in biochemical research.
Originally designed to target growth hormone release pathways more selectively than other peptides such as GHRP-6 or ghrelin mimetics, ipamorelin has been primarily studied in preclinical contexts involving tissue regeneration and metabolic modulation. Its selective profile reduces the likelihood of side effects commonly associated with broader secretagogues, making it an attractive molecule for experimental investigation.
In research settings, ipamorelin is primarily employed to study its effects on the somatotropic axis, particularly its capacity to induce growth hormone secretion and subsequent activation of downstream mediators such as insulin-like growth factor 1 (IGF-1). These pathways are relevant to cellular proliferation, satellite cell activation, and tissue repair mechanisms, especially within musculoskeletal research models.
Researchers also investigate ipamorelin’s role in modulating body composition and metabolic parameters in models of hypogonadism and aging, where growth hormone deficiencies contribute to pathological changes. Due to its selective receptor activity and favorable preclinical safety profile, ipamorelin remains a focus of ongoing laboratory research exploring growth hormone secretagogues’ therapeutic potential.
Key Benefits & Mechanisms
- Promotion of Tissue RegenerationPreclinical studies suggest ipamorelin enhances tissue regeneration by stimulating growth hormone release, which activates IGF-1 signaling pathways. This cascade supports satellite cell proliferation and repair processes critical for recovery in musculoskeletal injury models.
- Potential Improvement in Body CompositionResearch indicates that ipamorelin can positively influence body composition by promoting lean muscle mass accretion and reducing fat accumulation. These effects are particularly studied in models of hypogonadism and metabolic syndrome, where growth hormone signaling is impaired.
- Selective Growth Hormone ReleaseUnlike some other growth hormone secretagogues, ipamorelin demonstrates high selectivity for growth hormone release with minimal impact on cortisol or prolactin levels, reducing the risk of hormonal side effects in research models and enabling clearer study of growth hormone-mediated pathways.
- Support for Musculoskeletal HealingIpamorelin’s stimulation of growth hormone and IGF-1 pathways aids cellular proliferation and satellite cell repair mechanisms, which are vital for musculoskeletal healing. This has made it a compound of interest in orthopaedic and sports medicine research contexts focused on regenerative therapies.
- Research Tool for Somatotropic Axis ModulationIpamorelin serves as a valuable research compound to dissect the molecular mechanisms regulating the somatotropic axis, providing insights into growth hormone dynamics, receptor interactions, and downstream signaling relevant to regenerative biology and endocrinology.
Mechanism of action
Ipamorelin exerts its effects by acting as a growth hormone secretagogue, selectively binding to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. This interaction stimulates the release of endogenous growth hormone, which subsequently activates insulin-like growth factor 1 (IGF-1) signaling pathways in peripheral tissues. The IGF-1 pathway promotes cellular proliferation, differentiation, and satellite cell activation, processes essential for tissue regeneration and repair, particularly within musculoskeletal systems. Ipamorelin's selective receptor affinity results in a focused stimulation of growth hormone secretion without significantly elevating other pituitary hormones such as cortisol or prolactin, thereby minimizing off-target hormonal effects in preclinical models.
Research Summary
Research on ipamorelin has advanced understanding of growth hormone secretagogues in tissue regeneration and metabolic regulation. The 2026 review titled "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions" highlights ipamorelin among growth hormone secretagogues that activate IGF-1 signaling and satellite cell repair, emphasizing its potential in musculoskeletal healing despite the current lack of clinical trials.
In the 2026 article "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians," ipamorelin is discussed alongside other peptides for its role in regenerative medicine and sports performance. While clinical evidence remains limited, preclinical research supports its capacity to enhance growth hormone levels and promote repair mechanisms relevant to orthopaedic injuries.
The 2020 review "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males" explores ipamorelin’s potential as an adjunctive therapy to improve body composition in hypogonadal and eugonadal males. It underscores ipamorelin’s efficacy in stimulating growth hormone and IGF-1 secretion, which may counteract symptoms such as fat accumulation and muscle atrophy, though clinical data are presently sparse.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026) PubMed · PMID 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (2026) PubMed · PMID 41476424
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. (2020) PubMed · PMID 32257855
Dosing in Research Literature
In preclinical research involving ipamorelin, dosing protocols vary widely depending on the experimental model and study objectives. Animal studies frequently administer ipamorelin via subcutaneous or intraperitoneal injection at doses calibrated to elicit measurable growth hormone release, but precise standardization across studies is lacking.
Human research data remain limited and do not establish definitive dosing regimens. Available literature often references combination protocols with other peptides such as CJC-1295 to potentiate growth hormone secretion. Due to the investigational status of ipamorelin, dosing parameters remain experimental, requiring careful consideration of pharmacokinetics and receptor dynamics in specific research contexts.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about Ipamorelin
Is ipamorelin approved by the FDA for clinical use?
Ipamorelin is not approved by the U.S. Food and Drug Administration (FDA) for medical or clinical use. It is classified strictly as a research chemical intended for laboratory and preclinical investigation only.
What is the primary research focus of ipamorelin?
Research on ipamorelin centers on its ability to selectively stimulate growth hormone release, activating IGF-1 pathways that support tissue regeneration, muscle repair, and modulation of body composition in preclinical models.
How does ipamorelin differ from other growth hormone secretagogues?
Ipamorelin is distinguished by its selective agonism of the ghrelin receptor, resulting in targeted growth hormone release without significantly increasing cortisol or prolactin levels, which reduces potential side effects observed with less selective secretagogues.
Can ipamorelin be combined with other peptides in research?
Yes, ipamorelin is frequently studied in combination with peptides like CJC-1295, GHRP-2, or BPC-157 to investigate synergistic effects on growth hormone secretion and tissue healing pathways in experimental settings.
What are the storage and handling considerations for ipamorelin?
As a research peptide, ipamorelin should be stored under conditions recommended by manufacturers, typically refrigerated or frozen in lyophilized form to maintain stability. Proper laboratory handling protocols must be followed to preserve compound integrity.
What is known about ipamorelin’s safety profile in research?
Preclinical studies indicate ipamorelin has a favorable safety profile with minimal off-target hormonal effects due to its receptor selectivity; however, comprehensive toxicological data are limited and clinical safety remains unestablished.
In what research areas is ipamorelin primarily utilized?
Ipamorelin is primarily used in research investigating growth hormone dynamics, tissue regeneration, metabolic modulation, and experimental models of musculoskeletal injury and hypogonadism-related body composition changes.
Legal & research status: Research use only — not approved by the FDA for human use. Sold and discussed for laboratory and research use only, not for human consumption.